Press Releases

All Releases
View Summary MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
05/05/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Updates Status of New Drug Application for AFREZZA(R)
04/07/14
PDF 8.9 KB Add to Briefcase
View Summary FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
04/01/14
PDF 10.4 KB Add to Briefcase
View Summary MannKind Corporation to Present at Upcoming Conferences
02/19/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
02/18/14
PDF 17.7 KB Add to Briefcase
View Summary MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014
02/04/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA
01/10/14
PDF 8.0 KB Add to Briefcase
View Summary MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference
01/08/14
PDF 8.3 KB Add to Briefcase
View Summary MannKind Corporation to Present at The Piper Jaffray 25th Annual Healthcare Conference
11/27/13
PDF 8.7 KB Add to Briefcase
View Summary MannKind Corporation to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum
11/07/13
PDF 8.7 KB Add to Briefcase
View Summary MannKind Corporation Reports 2013 Third Quarter Financial Results
11/04/13
PDF 13.5 KB Add to Briefcase
View Summary MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA
10/30/13
PDF 9.0 KB Add to Briefcase
View Summary MannKind Corporation to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013
10/28/13
PDF 9.1 KB Add to Briefcase
View Summary MannKind Resubmits New Drug Application to U.S. FDA for AFREZZA for the Treatment of Adults with Diabetes
10/14/13
PDF 12.0 KB Add to Briefcase
View Summary MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
09/03/13
PDF 7.2 KB Add to Briefcase
View Summary MannKind Satisfies Conditions for Second Tranche of Convertible Note Financing
08/16/13
PDF 9.1 KB Add to Briefcase
View Summary MannKind Announces Positive Clinical Data for AFREZZA; Both AFFINITY Phase 3 Studies Meet Primary Endpoints
08/14/13
PDF 13.8 KB Add to Briefcase
View Summary MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes
08/14/13
PDF 15.6 KB Add to Briefcase
View Summary MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes
08/14/13
PDF 64.1 KB Add to Briefcase
View Summary CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes
08/14/13
PDF 62.6 KB Add to Briefcase
Showing 81-100 of 288 Page: 1 2 3 4 5 6 7 8 9 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

MNKD

Exchange:
NASDAQ GM and TASE(US Dollar)

Price: 0.50

Change: 0.01 (2.245%)

Volume: 9,246,897

Data as of
02/23/2017 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More